Related Experiment Video
Updated: Jan 21, 2026
07:59
Author Spotlight: Real-Time Monitoring of Parasite Burden and Host Response
Published on: May 31, 2024
2.0K
Drug discovery for chagas disease: A viewpoint
1Drugs for Neglected Diseases initiative (DNDi) Latin America, Rio de Janeiro, Brazil.
Acta Tropica
|July 28, 2019
Summary
Chagas disease, caused by Trypanosoma cruzi, urgently needs new treatments beyond current limited drugs. Greater research collaboration is essential to develop safe and effective therapies for this neglected tropical disease.
Area of Science:
- Neglected tropical diseases
- Parasitology
- Drug discovery
Background:
- Chagas disease is a significant global health issue caused by the protozoan parasite Trypanosoma cruzi.
- Current treatment options, benznidazole and nifurtimox, are limited and were developed over 110 years ago.
- Significant challenges, including a lack of understanding of disease pathophysiology and parasite-host interactions, hinder the development of new drugs.
Purpose of the Study:
- To highlight the unmet medical need for improved Chagas disease treatments.
- To discuss the challenges in developing new antiparasitic drugs for Chagas disease.
- To emphasize the necessity of increased collaboration within the research community.
Main Methods:
- Review of current treatment landscape for Chagas disease.
- Analysis of obstacles in preclinical drug development pipelines.
- Discussion of the importance of understanding disease mechanisms.
Main Results:
- Despite advances in knowledge, the pipeline for new Chagas disease drug candidates remains insufficient.
- The development of safe, effective, and accessible treatments is uncertain.
- Existing drugs have limitations, underscoring the need for novel therapeutic strategies.
Conclusions:
- There is a critical need for novel therapeutic agents to treat Chagas disease.
- Enhanced understanding of Chagas disease pathophysiology and parasite-host interactions is crucial.
- Increased collaboration among researchers is vital to accelerate the development of better treatments for patients.
Related Concept Videos
01:26Drug Discovery: Overview
11.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.2K
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
218
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
218
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
443
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
443
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
1.3K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.3K
01:31Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
643
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
However, this neutralization reaction between...
643
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
503
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
503